Treatment of Intracerebral Hemorrhage with Tranexamic Acid After Thrombolysis with Tissue Plasminogen Activator

• Published in: Neurocritical care Vol. 17; no. 1; pp. 107 - 111
• Main Authors: French, K. F., White, Jacob, Hoesch, R. E.
• Format: Journal Article
• Language: English
• Published: New York Humana Press Inc 01.08.2012; Springer Nature B.V
• Subjects: Acids; Antifibrinolytic Agents - administration & dosage; Antihypertensives; Bats; Blood products; Case reports; Cerebral Hemorrhage - chemically induced; Cerebral Hemorrhage - drug therapy; Computed tomography; Critical Care Medicine; Cryoprecipitates; Drug dosages; Drug Interactions; Edema; Fatal Outcome; FDA approval; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - adverse effects; Hematoma; Hemorrhage; Humans; Hypersensitivity; Hypertension; Intensive; Internal Medicine; Intravenous administration; Ischemia; Magnetic resonance imaging; Male; Medicine; Medicine & Public Health; Middle Aged; Neuroimaging; Neurology; Patients; plasminogen; Platelets; Practical Pearl; Stroke; subarachnoid hemorrhage; t-Plasminogen activator; thrombolysis; Thrombolytic Therapy - adverse effects; Thrombolytic Therapy - methods; Tissue Plasminogen Activator - administration & dosage; Tissue Plasminogen Activator - adverse effects; Tomography; Tranexamic Acid - administration & dosage; Trauma; United States > US; Critical care; Infarction; All cerebrovascular disease/stroke; Thrombolysis; Intracerebral hemorrhage
• ISSN: 1541-6933; 1556-0961
• DOI: 10.1007/s12028-012-9681-5

Background Thrombolytic treatment with intravenous tissue plasminogen activator (iv tPA) is the only FDA-approved therapy for acute ischemic stroke. There are risks associated with thrombolytics, including intracranial and extracranial hemorrhage and hypersensitivity reactions. Established treatment for post-tPA hemorrhage includes administration of blood products including cryoprecipitate, fresh frozen plasma, and platelets which have poorly established efficacy. Tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) have been studied as hemostatic therapies in post-operative hemorrhage, menorrhagia, intracranial hemorrhage (ICH), subarachnoid hemorrhage, and trauma patients. There is no reported literature on the use of TXA to reverse thrombolytic therapy with tPA. Methods This is a case report of a Jehovah’s Witness patient who was unwilling to receive blood products after developing symptomatic ICH following iv tPA. He consequently received TXA for reversal of thrombolytic therapy. Results The patient received a total of 1.675 g of iv TXA within 3 h of finishing the iv tPA. Repeat brain imaging with computed tomography and magnetic resonance imaging revealed no further expansion of hemorrhages. Conclusion TXA is an inexpensive medication which competitively inhibits the activation of plasminogen and can be given to reverse thrombolysis in the setting of hemorrhage after iv thrombolytic therapy.